|
| Press Releases |
|
 |
|
| Wednesday, July 16, 2025 |
|
|
A New Chapter Begins! CMS Achieves Secondary Listing on the Singapore Exchange Main Board Today |
| On the morning of 15 July 2025, China Medical System Holdings Limited ("CMS" or the "Group") rang the ceremonial bell to mark its official listing on the Singapore Exchange Main Board (Stock Abbreviation: CMS, Stock Code: 8A8). more info >> |
|
| Wednesday, June 25, 2025 |
|
|
China Medical System Holdings Limited: Proposed Secondary Listing on the Singapore Exchange |
| more info >> |
|
| Friday, March 21, 2025 |
|
|
China Medical System (00867) Released its 2024 Annual Results: Focusing on Innovation and Specialty Breakthroughs to Reshape Growth Momentum |
| On March 17, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 annual results. The Company recorded a turnover of RMB7,469 million, representing a year-on-year decrease of 6.8%; in the case that all medicines were directly sold by the Company, the turnover would be RMB8,622 million, representing a year-on-year decrease of 9.0%. more info >> |
|
| Friday, February 14, 2025 |
|
|
China Medical System (867.HK) is Included in the S&P Global Sustainability Yearbook 2025 |
| In February 11th 2025, with a Corporate Sustainability Assessment (CSA) score of 61, surpassing 93% of global peers, China Medical System Holdings Limited ("CMS" or the "Group") has been included in the S&P Global Sustainability Yearbook 2025 (the "Yearbook 2025"). more info >> |
|
| Friday, January 24, 2025 |
|
|
China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10 |
| China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10 more info >> |
|
| Thursday, January 9, 2025 |
|
|
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the "Agreement") with Alpha Cognition Inc. ("Alpha") of the improved new drug ZUNVEYL (benzgalantamine delayed-release tablets)("ZUNVEY" or the "Product") for the treatment of mild-to-moderate dementia of the Alzheimer's type. more info >> |
|
| Monday, December 9, 2024 |
|
|
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China |
| China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China more info >> |
|
| Monday, December 2, 2024 |
|
|
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia |
| China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia more info >> |
|
| Monday, October 21, 2024 |
|
|
China Medical System: First Ruxolitinib Cream's Prescriptions for Vitiligo Issued in the Greater Bay Area |
| China Medical System Holdings Limited (the "Group" or "CMS") is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. more info >> |
|
| Tuesday, September 24, 2024 |
|
|
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Trading Central Launches FIBI: AI-Powered Financial Assistant Live Across Research Tools 
Sept 16, 2025 09:15 HKT/SGT
|
|
|
How Not to Lose the Billion Dollars You Didn't Know You Had - Groundbreaking Guide to Protecting Family Fortunes
Sept 16, 2025 08:30 HKT/SGT
|
|
|
JSR Corporation/Inpria Corporation and Lam Research Enter Cross Licensing and Collaboration Agreement to Advance Semiconductor Manufacturing
Sept 16, 2025 9:00 JST
|
|
|
GMG Announces Graphene Coating Patent Approval and Customer Case Study Successes
Sept 15, 2025 20:09 HKT/SGT
|
|
|
CTF Life+ Initiative Strengthens Company Connections with the Younger Generation
Sept 15, 2025 17:33 HKT/SGT
|
|
|
Focus Graphite and C4V Report Breakthrough Early Results Showing 26% Improvement in LFP Cathode Density Using Lac Knife Cathode Ultima
Sept 15, 2025 17:09 HKT/SGT
|
|
|
HKTDC releases research report on biomedicine, Industry development drives GBA global tech leadership
Sept 15, 2025 15:19 HKT/SGT
|
|
|
Toyota Launches Next-Generation New Mobility e-Palette
Sept 15, 2025 15:33 JST
|
|
|
Announcing the results of the 42nd Hong Kong Watch and Clock Design Competition
Sept 15, 2025 11:27 HKT/SGT
|
|
|
Submarine Networks World 2025 - the annual flagship event for the global subsea industry returns to Singapore in September.
Sept 15, 2025 08:00 HKT/SGT
|
|
|
The University of Osaka D3 Center Commences Operation of New Computing and Data Infrastructure Built by NEC
Sept 12, 2025 15:08 JST
|
|
|
GR Yaris "Aero performance package" Set for Japan Launch
Sept 12, 2025 14:40 JST
|
|
|
Mitsubishi Heavy Industries Achieves Target Performance at Pilot Plant for Bioethanol Membrane Dehydration Systems
Sept 12, 2025 14:19 JST
|
|
|
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
Sept 12, 2025 13:20 JST
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES Succeeds in Developing High-Performance Palladium Alloy Hydrogen Permeable Membrane Operable in the Low-Temperature Range of 300 degrees C
Sept 12, 2025 11:00 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
